Basal cell carcinoma (BCC) is the most common malignant tumour in white populations.
Multidisciplinary experts from the European Dermatology Forum, the European Association …

Abstract Purpose of Review The therapeutic landscape for non-melanoma skin cancer
(NMSC) has recently expanded with the development of effective and targeted …

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the
clinical care of patients with cancer. However, whether the T cell response to checkpoint …

Understanding complex tissues requires single-cell deconstruction of gene regulation with
precision and scale. Here, we assess the performance of a massively parallel droplet-based …

Summary Background Before February, 2021, there was no standard treatment regimen for
locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy …

British Association of Dermatologists guidelines for the management of adults with basal cell
carcinoma 2021* | British Journal of Dermatology | Oxford Academic Skip to Main Content …

Non-melanoma skin cancer (NMSC) includes a wide range of cutaneous tumors, the most
frequent of which are basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma …

As the incidence of cutaneous malignancies continues to rise and their treatment with
immunotherapy expands, dermatologists and their patients are more likely to encounter …

Basal cell carcinoma (BCC) is the most common, accounting for 80–90% of skin cancers. It
arises from the basal layer of the epidermis and its appendages. A complex interplay of …

The basis of immune evasion, a hallmark of cancer, can differ even when cancers arise from
one cell type such as in the human skin keratinocyte carcinomas: basal and squamous cell …